Clinical Context
A 42-year-old adult presents to a neurology clinic with progressive cerebellar ataxia characterized by gait instability, dysarthria, and gradual coordination decline over several years. A family history is notable for similar late-onset neurodegenerative symptoms in a parent. The neurologist documents signs consistent with spinocerebellar ataxia and orders molecular diagnostic testing to evaluate for expanded CAG repeat alleles in the ATXN1 gene.
The clinical workflow begins with pre-test genetic counseling to explain indications, possible results, and implications for family members. A blood sample is collected in the outpatient lab and sent to a molecular diagnostics laboratory. The lab analyst performs the technical assay to detect expanded sequence changes in the ATXN1 gene using PCR-based sizing or fragment analysis, capillary electrophoresis, or other validated methods. Results are reviewed by the laboratory director and a written report detailing allele sizes, interpretation (normal, intermediate, or expanded pathogenic allele), and recommended follow-up is returned to the ordering clinician. Post-test genetic counseling is typically provided to discuss results, implications for prognosis, and familial testing options.
Typical site of service: outpatient physician office, outpatient draw station, or reference molecular diagnostics laboratory (off-site). Service type: diagnostic molecular genetic testing for detection of expanded alleles in the ATXN1 gene relevant to spinocerebellar ataxia type 1 (SCA1).